InVivo Therapeutics Holdings Corporation (NVIV) |
| 0.3207 -0.167 (-34.28%) 02-12 16:00 |
| Open: | 0.4081 |
| High: | 0.409 |
| Low: | 0.301 |
| Volume: | 1,609,868 |
| Market Cap: | 1(M) |
| PE Ratio: | -0.1 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 15.80 |
| Resistance 1: | 14.74 |
| Pivot price: | 13.37 |
| Support 1: | 13.02 |
| Support 2: | 10.84 |
| 52w High: | 2.4 |
| 52w Low: | 0.22 |
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Financials
| EPS | 0.780 |
| Book Value | 4.140 |
| PEG Ratio | 1.07 |
| Gross Profit | 18.306 |
| Profit Margin (%) | 10.50 |
| Operating Margin (%) | 15.05 |
| Return on Assets (ttm) | 5.3 |
| Return on Equity (ttm) | 9.3 |
Company news
Tue, 26 Mar 2024
InVivo Therapeutics Holdings Corp (NASDAQ: NVIV) - Share Price - intelligentinvestor.com.au
Tue, 06 Feb 2024
Bob Langer-founded device-maker declares bankruptcy - The Business Journals
Thu, 09 Mar 2023
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury - Business Wire
Wed, 13 Jul 2022
InVivo Therapeutics Appoints Heather M. Hamel as Chief Legal Officer - citybiz
Mon, 18 Apr 2022
Monday's session: gap up and gap down stocks - ChartMill
Mon, 18 Apr 2022
These stocks are moving in today's pre-market session - ChartMill
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
